SOURCE: Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

March 09, 2015 08:30 ET

ETC-1002-008 Phase 2b Results to be Presented at the American College of Cardiology 64th Annual Scientific Session

Company to Host Webcast on Saturday, March 14, 2015 at 7:00 p.m. Pacific Time/10:00 p.m. Eastern Time

ANN ARBOR, MI--(Marketwired - March 09, 2015) - Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced Dr. Paul Thompson, director of cardiology at Hartford Hospital, will present full results from the Phase 2b ETC-1002-008 clinical study during the American College of Cardiology 64th Annual Scientific Session. The abstract, "ETC-1002 Lowers LDL-C More than Ezetimibe in Patients with Hypercholesterolemia with or without Statin Intolerance," will be presented in a moderated poster session (Session # 1164M) on Saturday, March 14, 2015 at 3:45 p.m. at the San Diego Convention Center in the Prevention Moderated Poster Theater.

On October 1, 2014, the Company announced positive top-line results from ETC-1002-008 -- a clinical study that evaluated the efficacy and safety of ETC-1002 monotherapy versus ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance -- demonstrating ETC-1002-treated patients achieved LDL-cholesterol lowering of up to 30 percent at 12 weeks compared with 21 percent in the ezetimibe group, and up to 48 percent when ETC-1002 was added to ezetimibe. Levels of hsCRP were reduced by up to 40 percent with ETC-1002 both as monotherapy and in combination with ezetimibe.

Conference Call and Webcast Information

Esperion will host a live webcast briefing of the Phase 2b ETC-1002-008 clinical study results, featuring Dr. Paul Thompson and Tim M. Mayleben, president and chief executive officer of Esperion, who will provide analysis from the study, and a program update on ETC-1002, including the development of a fixed dose combination with ezetimibe. The event will take place on Saturday, March 14, 2015 at 7:00 p.m. Pacific Time/10:00 p.m. Eastern Time. The webcast can be accessed by dialing (877) 831-3840 (domestic) or (253) 237-1184 (international) five minutes prior to the start and providing access code 3658776. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the Esperion website at www.esperion.com. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the Company's website for 90 days following the event.

About ETC-1002-008

The randomized, double-blind, active comparator-controlled, parallel group, multicenter Phase 2b study evaluated the efficacy and safety of ETC-1002 monotherapy versus ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance, treated for 12 weeks. Secondary objectives were to characterize the dose response; assess the effect of ETC-1002 on additional lipid and cardiometabolic biomarkers; characterize the safety, tolerability and rates of muscle-related adverse events; and assess lipid-lowering efficacy in combination with ezetimibe versus ezetimibe monotherapy. Esperion previously announced positive top-line results from this study on October 1, 2014, which demonstrated ETC-1002- treated patients achieved LDL-cholesterol lowering of up to 30 percent at 12 weeks compared with 21 percent in the ezetimibe group, and LDL-cholesterol reductions of up to 48 percent when ETC-1002 was added to ezetimibe. Levels of hsCRP were reduced by up to 40 percent with ETC-1002 both as monotherapy and in combination with ezetimibe.

Esperion's Commitment to Cardiometabolic Disease

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with therapies currently available for lowering LDL-cholesterol. ETC-1002 is being developed primarily for patients with hypercholesterolemia and a history of statin intolerance. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.

Contact Information